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Background: Several past clinical studies have demonstrated that frequent and unnecessary right ventricular
pacing in patients with sick sinus syndrome and compromised atrio-ventricular conduction (AVC) produces
long-term adverse effects. The safety and efﬁcacy of two pacemaker algorithms, Ventricular Intrinsic Pre-
ference™ (VIP) and Ventricular AutoCapture (VAC), were evaluated in a multi-center study in pacemaker
patients.
Methods: We evaluated 80 patients across 10 centers in India. Patients were enrolled within 15 days of dual
chamber pacemaker (DDDR) implantation, and within 45 days thereafter were classiﬁed to either a com-
promised AVC (cAVC) arm or an intact AVC (iAVC) arm based on intrinsic paced/sensed (AV/PV) delays. In
each arm, patients were then randomized (1:1) into the following groups: VIP OFF and VAC OFF (Control
group; CG), or VIP ON and VAC ON (Treatment Group; TG). Subsequently, the AV/PV delays in the CG groups
were mandatorily programmed at 180/150 ms, and to up to 350 ms in the TG groups. The percentage of right
ventricular pacing (%RVp) evaluated at 12-month post-implantation follow-ups were compared between the
two groups in each arm. Additionally, in-clinic time required for collecting device data was compared
between patients programmed with the automated AutoCapture algorithm activated (VAC ON) vs. the
manually programmed method (VAC OFF).
Results: Patients randomized to the TG with the VIP algorithm activated exhibited a signiﬁcantly lower %RVp
at 12 months than those in the CG in both the cAVC arm (39741% vs. 9773%; p¼0.0004) and the iAVC arm
(15725% vs. 68739%; p¼0.0067). In-clinic time required to collect device datawas less in patients with the
VAC algorithm activated. No device-related adverse events were reported during the year-long study period.
Conclusions: In our study cohort, the use of the VIP algorithm signiﬁcantly reduced the %RVp, while the VAC
algorithm reduced in-clinic time needed to collect device data.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.blished by Elsevier B.V. All rights
pital, Sec-B, Pocket 1, Aruna
ndia. Tel: þ91 9811150518;
).1. Introduction
Several clinical studies (Danish I [1,2] Danish II [3,4] DAVID [5],
MOST sub-analysis [6], MADIT II Substudy [7,8]) have demonstrated
that frequent and unnecessary pacemaker right ventricular pacing
(RVp) in patients with sinus node disease and atrio-ventricular (AV)
block can lead to long-term adverse effects, including atrial ﬁbrilla-
tion (AF) and heart failure. Ventricular dyssynchrony caused byreserved.
R. Yadav et al. / Journal of Arrhythmia 32 (2016) 29–3530unnecessary RVp causes valvular regurgitation followed by left atrial
enlargement and remodeling, which predisposes patients to AF. In
addition, these patients are at a greater risk of developing congestive
heart failure due to altered cardiac hemodynamics caused by ven-
tricular dyssynchrony [3,5,6]. One option to reduce the percentage of
RVp in patients with sick sinus syndrome (SSS) but with normal AV
conduction (AVC) is to establish functional AAIR (NBG code for sin-
gle-chamber atrial inhibited pacing with rate modulation) pacing by
using the DDDR (NBG code for dual chamber pacing with atrial
tracking and rate modulation) mode with a long AV delay. However,
in patients with diseased intrinsic AVC, RVp with excessive AV delays
may result in non-physiological AV delays and further deterioration
in ventricular hemodynamics [3,9].
Two different pacemaker concepts have evolved to promote
intrinsic conduction and pacing with a reasonable AV delay when
needed: AV hysteresis algorithms and algorithms based on the AAI/
DDD (mode switch. AV hysteresis algorithms essentially work with
two different AV delays; a shorter AV delay to provide optimal
hemodynamics with ventricular pacing, and a longer AV delay to
promote intrinsic conduction. AAI/DDD mode switch-based features
do not trigger an AV delay, and therefore allow very long AV delays
and pauses of up to 3 s. Clinical data for both strategies are mainly
conﬁned to small studies evaluating safety and efﬁcacy, and have
demonstrated low ventricular pacing percentages [10,11].
The two algorithms, “Ventricular Intrinsic Preference™ (VIP)”
and “Ventricular AutoCapture (VAC)”, represent enhanced features
of DDDR pacemakers. The VIP algorithm monitors intrinsic cardiac
rhythm and provides pacing when required, thereby activating/
deactivating on a beat-by-beat basis. It works upon AV hysteresis,
in which the AV delay is varied to a level just longer than the
intrinsic AV delay, thereby promoting intrinsic conduction. The VIP
algorithm is deactivated when the number of VP events becomes
equals to the number of programmed search cycles at the exten-
ded AV delay. In contrast, the VAC algorithm senses beats and
increases the amplitude [by 1/4 (0.25) V for one beat]. Further-
more, if the capture is conﬁrmed, the pacemaker delivers the same
amplitude again to re-conﬁrm the capture. After the capture is
conﬁrmed, a threshold search is initiated. During the search, the
pulse amplitude is decreased by 1/4 (0.25) V two beats at a time
until the capture is lost for two consecutive beats. The pulse
amplitude is then increased by 1/8 (0.125) V-increments until two
consecutive captured beats are present (this is known as the
“capture threshold”). The amplitude is then set 1/4 (0.25) V above
the threshold and established a working safety margin.
In the present study (Evaluation of VentriculAr Intrinsic Pre-
ference Plus VentricuLar AutoCapture Features In Dual ChAmber
Pacemaker PaTiEnts-VALIDATE), we evaluated the effects of the
VIP algorithm in the management of dual chamber pacemaker
patients. Additionally, the impact of the VAC algorithm on in-clinic
time was evaluated at 6 and 12 months.2. Material and methods
This was a prospective, randomized, single-blinded, multicenter
study conducted at 10 centers in India. Prior to patient enrollment,
appropriate institutional review board approval for the protocol,
patient information sheets, and consent forms was obtained. The
study was conducted in accordance with the Declaration of Helsinki,
ISO 14155, and all local requirements including registration on the
public domain Clinical Trials Registry of India (www.ctri.nic.in;
reference number: CTRI/2010/091/000179) before the 1st patient
was enrolled. The study protocol was approved by the Institutional
Ethics Committee (from May, 2010 to March 2011) of all centers
concerned prior to the initiation of the study at their respective sites.2.1. Patient selection
From July 2010 to July 2011 consecutive patients who had an
indication for dual chamber pacemaker implantation according to
the ACC/AHA/HRS guidelines and who were geographically stable,
willing to provide written informed consent, and complied with the
required follow up schedule were invited to participate in the study.
Patients with permanent AV block, persistent or permanent AF/atrial
ﬂutter (AFL), pacemaker replacement, New York Heart Association
classiﬁcation (NYHA) class IV, current pregnancy, ageo18 years, and
life expectancyo12 months were excluded from the study.
In order to standardize the device-based diagnostics used to
evaluate study endpoints, only patients with either a Zephyr DR
5820 model or Zephyr XL DR 5826 model implant manufactured
by St. Jude Medical, Inc. were invited to participate in the study
(within 15 d of pacemaker implantation). After obtaining informed
consent, patients’ demographic data regarding age, weight, height,
gender, NYHA class, and blood pressure were recorded. Addition-
ally, relevant patient data on pacemaker implant indications
(rhythm/conduction disorder), right atrium and right ventricle
lead position (chest X-ray), medical history including atrial
tachyarrhythmia (AF/AFL), 12 lead electrocardiograms (ECGs),
echocardiography (left ventricle ejection fraction [LVEF]), and
ongoing cardiovascular medication were collected.
2.2. Device characteristics
The device was inspected post-implantation, which included
real-time measurements of atrial and ventricular pacing, sensing
thresholds, and lead impedance. An over-sensing test was per-
formed to optimize the device's sensing performance to ensure
that there was no ventricular signal detected on the atrial channel.
The pacemakers were programmed to the DDD(R) mode with a
base rate of r60 bpm and with the paced/sensed AV delay set at
180/150 ms (Table 1).
2.3. Randomization
Within 45 d post-implantation, patients returned for a rando-
mization visit, during which the patient’s data regarding NYHA
class, blood pressure, 12 lead ECG, ongoing cardiovascular medi-
cations, and adverse events (AEs) were collected.
Based on an AVC test, all enrolled patients were stratiﬁed to
either the compromised AVC (cAVC) arm or the intact AVC (iAVC)
arm. This was performed based on the intrinsic paced/sensed (AV/
PV) delay (if measurable) and the results of AVC testing. Patients
with an AV/PV delay4210 ms or with no intrinsic conduction on
surface ECG were placed in the cAVC armwhile patients with an AV/
PV delayr210 ms were further evaluated during an AVC test to
ensure 1:1 AVC during temporary atrial pacing. The test was started
at a sinus rate of þ10 bpm and was then increased by increments of
10 bpm until either 120 bpm was reached or Wenckebach behavior
was observed. Patients in whom 1:1 AV conduction was lost during
the test were randomized to the cAVC arm, while all other patients
were randomized to the iAVC arm, unless patients in whom the
ventricular R wave interval was Z350ms, or with ventricular pacing
at any time during the AVC test.
Furthermore, each arm was classiﬁed into a Control group (CG:
VIP OFFþVAC OFF) and a Treatment group (TG: VIP ONþVAC ON)
at a 1:1 ratio using stratiﬁed permutated block randomization.
In the TG, both VIP and VAC were activated. AV delay prolonga-
tion was set at 350 ms with the search cycle and search interval set
to 3 and 30 s, respectively. As VAC provides ﬂexibility with Beat-by-
Beat™ capture veriﬁcation, an autocapture setup test was performed
to ensure that VAC could be activated in each patient.
Table 1
Baseline device programming.
Basic parameters
Mode DDD(R)
Base rate r60
Max track rate 220-Age*0.8 or 0.9
Paced AV delay 180 ms
Sensed AV delay 150 ms
Rate responsive AV/PV delay OFF
Atrial refractory (PVARP) 275 ms
RR PVARP Medium
Atrial sensitivity 0.3 mV
Extended parameters
Auto mode switch DDI (R)
Atrial tachycardia detection rate 20 bpm above max tracking rate or 180 bpm
AF Supression™ OFF
Post Vent. Atrial Blanking Optimized (Oversensing test)
PMT options Autodetect
Stored EGMs parameters
Sampling options Continuous
No. of stored EGMs 8
Maximum duration 6 s
Channel Dual
Atrial EGM conﬁguration A.Bipolar
Atrial dynamic range 73.0 mV
Vent. EGM conﬁguration V.Bipolar
Vent. dynamic range 715.0 mV
PMT detection ON
High ventricular rate ON (175 bpm)
Number of consecutive cycles 10
AT/AF detection ON
Additional parameters (randomization)
VIP™ CG TG
Prolongation N/A Open
Search cycles N/A 30 s
Search interval N/A 3
Ventricular autocapture OFF ON
AV – Atrio-ventricular, AF – atrial ﬁbrillation, AT – atrial tachycardia, CG – Control
group, EGM – Electrogram, N/A – Not applicable, PV – Paced delay, PMT – Pace-
maker mediated tachycardia, VIP – Ventricular Intrinsic Preference algorithm, TG –
Treatment Group.
Fig. 1. Study ﬂow chart. The ﬁgure depicts study ﬂow chart. It illustrates the study d
conduction were divided into either Compromised AV Conduction arm or Intact AV Cond
(TG) and VIP OFFþVAC OFF group (CG).
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visit was performed. The in-clinic time required to measure the ven-
tricular capture threshold using a manual decrement test was noted.
Subsequently, the time for updating the threshold values by VAC
algorithm were noted to be automated. A comparison between the
two (manual and automated) was carried out. When an automated
value was observed to be more than the manual value by 0.25, it was
determined to be 100% accuracy.
All patients were followed-up at 3, 6, and 12 months post-
implantation and the tests performed at the randomization visit
were repeated, except the AVC test, which was not performed at
the 3 month follow-up visit.
2.4. Sample size calculation
The sample size estimation was based on the primary endpoint
and study design, comparing %RVp at 12 months between the VIP
ONþVAC ON group (TG) and the VIP OFFþVAC OFF group (CG) for
the patients with compromised AVC, as well as for patients with
intact AVC. The %RVps reported in the cAVC arm of a previous study
[12] were 32736 and 82729 for TG and CG, respectively, while
those in the iAVC arm were 12726 and 58737 for the TG and CG,
respectively. In order to detect similar difference in %RVp between
the TG and CG in the present study, at least 11 patients from each
group were required in the cAVC arm and at least 12 patients from
each group were required in the iAVC arm to maintain a joint power
of 90% and a signiﬁcance level of 5%. With a dropout rate of 15%
every 6 months, 80 patients needed to be recruited in total (Fig. 1).
2.5. Statistical methods
The primary endpoint was summarized using descriptive sta-
tistics (mean, standard deviations, medians, ranges) and compar-
isons between the groups were performed using the unpaired t-
test when data were normally distributed. When data were not
normally distributed, the equivalent nonparametric test (Wilcoxon
rank sum test) was used. Data were checked for normality using
box plots, normal quartile plots, and normality tests. Comparisonsesign, according to which the patients based on their intrinsic Atrio-ventricular
uction arm. In both arms patient were then randomized to VIP ONþVAC ON group
Table 2
Baseline demographic data.
Patient’s
characteristics
Randomized group
cAVC p-Value iAVC p-Value
CG TG CG TG
N¼22 N¼25 N¼15 N¼16
Gender (n/%)
Female
7/31 6/24 0.55 7/46 5/31 0.38
Age (years)€
Mean7SD
65712 66713 0.70 6379 65711 0.56
Height (cm)d
Mean7SD
16278 16378 162713 16279
Weight (kg)
Mean7SD
65716 61710 66716 5779
Systolic blood
pressure (Hg)
Mean7SD
129717 123716 0.23 125717 121717 0.47
Diastolic blood
pressure (Hg)
Mean7SD
74.77 72711 0.48 74711 7478 0.92
LVEF (%)¥
Mean7SD
54713 5278 0.66 5877 5878 0.80
LVESD (mm)¥
Mean7SD
2575 3075 0.07 2776 2975 0.29
LVEDD (mm)¥
Mean7SD
4073 4774 0.23 3779 4272 0.61
Pacemaker implant indication (n/%)α
Sick sinus
syndrome
7/31 17/68 5/33 10/62
Sinus
bradycardia
4/18 13/52 4/26 6/37
SA block/sinus
arrest
3/13 5/20 1/6 5/31
Intermittent AV-
block
14/63 6/24 8/53 6/37
NYHA class (n/%)
I 13/59 14/56 8/53 12/75
II 9/40 6/24 6/40 2/12
III 0/0 3/12 1/6 2/12
Unknown 0/0 2/8 0.21 0/0 0/0 0.31
P value
Medical history (n/%)
None 3/13 4/16 0/0 5/31
Hypertension 14/63 16/64 8/53 7/43
CAD 6/27 7/28 5/33 3/18
HCM 0/0 1/4 0/0 0/0
TIA/RIND/CVA/
stroke
0/0 1/4 0/0 0/0
MI 1/4 1/4 2/13 1/6
Diabetes
mellitus
7/31 9/36 7/46 3/18
Renal
insufﬁciency
1/4 0/0 0/0 0/0
Valve disease 0/0 1/4 0/0 0/0
Cardiac surgery 3/13 5/20 2/13 2/12
Other 7/31 6/24 6/40 5/31
Medication
ACE-inhibitors/
ARB
11 11 7 6
Amiodarone 0 1 1 3
Anticoagulant 3 6 3 1
Anti-platelets 5 9 3 5
Beta-blocker 3 6 3 5
AV – Atrio-ventricular, ACE – Angiotensin converting enzyme, ARB – Angiotensin
receptor blocker, cAVC – Compromised Atrio-ventricular conduction, CAD – Cor-
onary artery disease, CVA – Cerebrovascular accident, CG – Control group, HCM –
Hypertrophic cardiomyopathy, iAVC – Intact Atrio-ventricular conduction, LVEF –
Left ventricular ejection fraction, LVESD – Left ventricular end systolic diameter,
LVEDD – Left ventricular end diastolic diameter, MI – Myocardial ischemia, N –
Number, NYHA – New York Heart association, RIND – Reversible Ischemic Neuro-
logic Deﬁcit, SA – Sino-atrial, SD – Standard Deviation, TG – Treatment Group, TIA –
Transient ischemic attack.
€ Age was calculated by subtracting the date of the baseline visit with the date
of birth divided by 365.25 (because of the leap years).
d Baseline data not available for 1 patient in the AVC VIP ONþVAC ON
Group.
¥ Echo data is not available for all patients as it was not mandatory protocol
requirement.
α Multiple choices may have been checked for each patient.
R. Yadav et al. / Journal of Arrhythmia 32 (2016) 29–3532were expressed in p-values, and the null hypothesis was rejected if
the p-value was less than 0.05. All continuous variables are
expressed as mean7standard deviations. All categorical data were
presented using frequencies and percentages.3. Results
3.1. Study population
A total of 80 patients were recruited at 10 centers in India.
Seventy-eight of these patients were randomized (two patients
withdrew their consent prior to randomization visit due to non-
study related reasons). Seventy-one patients completed the 12
month follow-up period. Data for seven patients were not avail-
able as there were four deaths and four losses to follow-up. Thirty-
seven patients were randomized to the CG and forty one to the TG.
The baseline characteristics, such as age, height, weight, dia-
stolic/systolic blood pressure, LVEF, NYHA class, medical history,
and medication are described in Table 2.
Post-implantation, 12-lead ECGs were reviewed by physicians
for cardiac rhythm, which showed that in the cAVC arm, seven
patients had sensed AV, 21 had sensed atrial and paced ventricle,
seven had paced atrial and sensed ventricle, and none had paced
AV. In contrast, in the iAVC arm, 10 patients had sensed AV, 13 had
sensed atrial and paced ventricle, six had paced atrium and sensed
ventricle, and only one had paced AV.
Activating VIP resulted in a signiﬁcant reduction of %RVp after
12 months in both the cAVC and iAVC arms. In the iAVC arm, VIP
reduced the %RVp from 68739% in the CG to 15725% in the TG
(p¼0.0067). In the cAVC arm, VIP reduced the %RVp from 9773%
in the CG to 39741% in TG (p¼0.0004) (Figs. 2 and 3). The %RVp
at the 6-month follow-up visit showed much lower percentages
than at the 12-month follow-up visit (Table 3).
3.2. Manual in-clinic time vs. automated in-clinic time in the
treatment group
Within the TG of the cAVC arm, the difference between the
manual and automated in-clinic time was 49734 min, 37717 min,
32713 min, and 24711 min at the randomization visit, 3-month
follow-up, 6-month follow-up, and 12-month follow-up, respec-
tively. Similarly, for the TG of the iAVC arm, the difference between
the manual and automated in-clinic time was 53738 min,
41727 min, 3077 min, and 31713 min for the respective visits.
This shows that less time was required to retrieve the device mea-
surements in-clinic by the automated method than the manual
method (po0.001 within iAVC and cAVC arms) (Table 4).
3.3. Percentage of VAC accuracy (V) in ventricular pacing threshold
measurements (manual vs. automatic methods)
The mean VAC accuracy for the ventricular pacing threshold in
the cAVC (TG) and iAVC (TG) arms was 126% (n¼25) and 100%
(n¼14) at randomization, 99% (n¼19) and 104% (n¼14) at the
3-month follow-up, 100% (n¼20) and 100% (n¼11) at the 6-month
follow-up, and 100% (n¼22) and 101% (n¼13) at the 12-month
follow-up, respectively (Table 4).
Fig. 2. Mean7SD plot of percentage of RV pacing over study period. The ﬁgure depicts signiﬁcant reduction of %RVp at 12-Month follow up when VIP algorithm was
activated in both cAVC & iAVC arms. In the iAVC group, %RVp was reduced by VIP from 68þ39% in CG to 15725% in TG (p¼0.0067). In the cAVC group, VIP reduced the %RVp
from 9773% in CG to 39741% in TG (p¼0.0004).
Fig. 3. Box plot for percentage of RV pacing at 6-Month & 12-Month visit. the ﬁgure depicts box plot representation for signiﬁcant reduction of %RVp at 12-Month follow up
when VIP algorithm was activated in both cAVC & iAVC arms. In the iAVC group, %RVp was reduced by VIP from 68þ39% in CG to 15725% in TG (p¼0.0067). In the cAVC
group, VIP reduced the %RVp from 9773% in CG to 39741% in TG (p¼0.0004).
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A total of 18 serious adverse events (SAE) were reported over
the course of the study period, including ﬁve cardiovascular AEs,
four (16%) in patients from the ‘cAVC – TG’ group, and one in (6%) a
patient from the ‘iAVC – TG’ group. No device-related AEs were
reported during the study period. One SAE was reported prior to
the randomization visit. In the TG of the cAVC arm, one (4%) death
occurred, whereas two deaths occurred in the TG of the iAVC arm
(13%). Seven of 25 patients in the TG of the cAVC arm and 1/16
patients in the TG of the iAVC-arm were hospitalized at least once
during the course of the study; all of these hospitalizations were
found not to be related to the study.4. Discussion
RVp has been a clinical standard for many decades. Clinical stu-
dies conducted in the last decade have highlighted the beneﬁt of
reducing RVp in patients who do not require ventricular pacing [13].
Different studied conducted across the world support the view thatfrequent RVp may have-long term side effects, including an increased
risk of developing AF or congestive heart failure [2,6,14].
The VIP Algorithm is based on AV hysteresis, and works by
enhances the promotion of intrinsic conduction [15–17]. The
enhanced VAC features an algorithm designed to conﬁrm a response
to each and every pacing stimulus, as well as automatically adjust the
output in response to changes in the capture threshold, thereby
minimizing energy consumption and improving the longevity of the
device [14].
A previous study from St. Jude Medical (EVITA) demonstrated that
VIP provides allows medium and long term incidence of unnecessary
ventricular pacing in patients with intact AV conduction to be
reduced. The study also showed that the VIP reduces the percentage
of ventricular pacing from 64% with VIP deactivated to 9% with VIP
activated [15]. The VIP Study evaluated the efﬁcacy of VIP in reducing
unnecessary RVp, and determined whether patients would beneﬁt
from using VIP rather than a programmed AV/PV delay only. The VIP
algorithm reduced unnecessary RV pacing in pacemaker patients
with intact AVC by 81% [18].
We produced results similar to those of previous studies.
Activating VIP resulted in a signiﬁcant reduction in mean %RVp at
Table 3
Six-month and 12-month follow-up visit ventricular pacing for both groups.
Arm Group 6-month follow-up 12-month follow-up p-Value
N Mean7SD N Mean7SD (%)
cAVC CG 21 92721 21
n
9773 0.0004
TG 23 45743 23 39741
iAVC CG 15 67736 13 68739 0.0067
TG 12 9722 14 15725
cAVC – Compromised Atrio-ventricular conduction, CG – Control group, iAVC – Intact Atrio-ventricular conduction, N – Number, SD – Standard Deviation, TG – Treatment
Group.
n
Data not available for one patient.
Table 4
Secondary endpoint analysis.
Visit Difference between manual and automated in clinic time (min) within
treatment groups (TG)n
Individual visit VAC accuracy (V) for treatment group
cAVC – TG iAVC – TG cAVC – TG iAVC – TG
N Mean7SD N Mean7SD N Mean7SD AVD N Mean7SD AVD
Randomization 25 49734 15 53738 25 0.3870.71 0.1370.71 14 0.2570 0
Month 3 20 37717 14 41727 19 0.2470.03 0.0170.03 14 0.3870.47 0.1370.47
Month 6 22 32713 12 3077 22 0.2570. 0 11 0.2570 0
Month 12 22 24711 13 31713 22 0.2570.04 070.04 13 0.2670.03 0.0170.03
AVD – Absolute value difference, cAVC – Compromised Atrio-ventricular conduction, iAVC – Intact Atrio-ventricular conduction, CG – Control group, N – Number, SD –
Standard Deviation, TG – Treatment Group.
n
po0.0001 within iAVC and cAVC group.
R. Yadav et al. / Journal of Arrhythmia 32 (2016) 29–353412 months in patients with either compromised or intact AVC. At
6 months, %RVp was found to be 45743 in the cAVC arm and
9722 in the iAVC arm.
The in-clinic time required to retrieve device measurements by
automated and manual methods showed that less time was required
to retrieve the device measurements via the automated method. A
total of 18 AEs were reported, although none was device-related.
As in previous studies [13,19], we showed that keeping VIP
activated signiﬁcantly reduces ventricular pacing in patients with
compromised or intact AV conduction, and that this reduction may
be sustained over a 12-month period. Of the 23 patients with
compromised AVC and pacemaker algorithms activated, only 17%
ventricular pacing was observed. This shows that in the TG,
intrinsic ventricular conduction was encouraged most of the time.
4.1. Limitations
An overall drop-out rate of 11% was observed during the course
of this study. The impact of drop-out rate on the study outcome is
unknown, as the overall ﬁndings are consistent with previous
studies. In our study, AV delay was pre-deﬁned in the protocol,
thereby allowing all investigators to make fair assessments. Unlike
in many other studies, shorter AV delay was programmed for the
control group (DDD/R mode), and (VIPþVAC ON) longer AV delay
was programmed for treatment group.
4.2. Programming recommendations
The VIP algorithm should be considered in patients with symp-
tomatic bradycardia including sinus node dysfunction and compro-
mised or intact AVC. VIP maximizes AV synchrony, and thereby
reduced unnecessary RV pacing. With the help VAC, all threshold
tests can be completed automatically. In addition, intrinsic signalsand lead impedances can be measured automatically, and trend can
be analyzed easily. The automated method should be considered, as
it can signiﬁcantly reduce the in-clinic time compared to manual
methods of device measurement collection.5. Conclusion
This study shows that VIP signiﬁcantly reduces %RVp in patients
with compromised as well as intact AVC. Avoiding RVp using
algorithms such as VIP will help to reduce cardiovascular events
related to unnecessary RVp. Ventricular autocapture also ensures
beat-by-beat veriﬁcation and adjusts the capture threshold to the
lowest effective output. In-clinic time can be reduced by selecting
the automated method instead of the manual method for retrieving
device measurements.Disclosure
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